Cover Image
市場調查報告書

慢性腎臟病造成之貧血 (腎性貧血):開發中產品分析

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363106
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
慢性腎臟病造成之貧血 (腎性貧血):開發中產品分析 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 131 Pages
簡介

本報告提供慢性腎臟病造成之貧血 (腎性貧血) 治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

慢性腎臟病造成之貧血 (腎性貧血)概要

治療藥的開發

  • 開發中產品的概要

慢性腎臟病造成之貧血 (腎性貧血):企業開發中的治療藥

慢性腎臟病造成之貧血 (腎性貧血):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

慢性腎臟病造成之貧血 (腎性貧血):企業開發中的產品

慢性腎臟病造成之貧血 (腎性貧血)治療藥的開發企業

  • 3SBio Inc.
  • Acceleron Pharma, Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Bayer AG
  • BIOCAD
  • CCM Duopharma Biotech Bhd.
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • 第一三共
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd.
  • 日本煙草產業
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • LG Life Science LTD.
  • Medgenics, Inc.
  • Myungmoon pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Pieris Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Zydus Cadila Healthcare Limited

慢性腎臟病造成之貧血 (腎性貧血):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

慢性腎臟病造成之貧血 (腎性貧血):暫停中的計劃

慢性腎臟病造成之貧血 (腎性貧血):中止開發的產品

慢性腎臟病造成之貧血 (腎性貧血):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8171IDB

Summary

Global Markets Direct's, 'Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016', provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia)
  • The report reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics and enlists all their major and minor projects
  • The report assesses Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Anemia in Chronic Kidney Disease (Renal Anemia) Overview
  • Therapeutics Development
    • Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Acceleron Pharma, Inc.
    • Akebia Therapeutics, Inc.
    • Amgen Inc.
    • Bayer AG
    • BIOCAD
    • CCM Duopharma Biotech Bhd.
    • Chong Kun Dang Pharmaceutical Corp.
    • CJ HealthCare Corp.
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Limited
    • Eli Lilly and Company
    • FibroGen, Inc.
    • GlaxoSmithKline Plc
    • Intas Pharmaceuticals Ltd.
    • Japan Tobacco Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Jiangsu Hansoh Pharmaceutical Co., Ltd.
    • LG Life Science LTD.
    • Medgenics, Inc.
    • Myungmoon pharmaceutical Co., Ltd.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • PharmaEssentia Corporation
    • Pieris Pharmaceuticals, Inc.
    • Sandoz International GmbH
    • Zydus Cadila Healthcare Limited
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • daprodustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1093 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPO-018B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin zeta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FG-2216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTZ-951 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBDE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3113593 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDGN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMP-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molidustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-1116 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peg-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roxadustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HIF-PH for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSS-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vadadustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
      • May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
      • Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings
      • Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication
      • Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat
      • Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat's Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease
      • Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program
      • Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting
      • Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia
      • Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis
      • May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress
      • Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN
      • Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat
      • Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease
      • Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics, Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by BIOCAD, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Eli Lilly and Company, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen, Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by LG Life Science LTD., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Medgenics, Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co., Ltd., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Limited, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corporation, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals, Inc., H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Sandoz International GmbH, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top